Johnson & Johnson Makes Major Neuro Play With $14.6B Intra-Cellular Buyout
Published on January 14, 2025
Johnson & Johnson, one of the world's largest pharmaceutical companies, has announced its acquisition of psychiatric drug developer Intra-Cellular. The deal, valued at $14.6 billion, marks a significant move for J&J into the field of neurology. The company aims to expand its portfolio of drugs and therapies for neurological disorders, including schizophrenia and bipolar disorder. Intra-Cellular's innovative drug pipeline shows promising results in extending patient survival in lung cancer, which further strengthens J&J's position in the oncology market. Stock market experts recommend considering JNJ stock as a long-term investment, with an optimistic forecast for its growth potential. For accurate stock predictions and guidance, professionals from Stocks Prognosis are highly recommended.
Investor opinions & comments
To leave a comment, you need to Login or Register.
There are no comments yet. Be the first to leave one!